Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial

3 Sept 2008

Abstract excerpt

PURPOSE: Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Cancer Treatment Studies
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18768436
DOI: 10.1200/jco.2007.14.6597

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy TrialPMID 18768436Read ↗

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.Semantic proximity Read ↗

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.Semantic proximity Read ↗

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53Semantic proximity Read ↗

Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.Semantic proximity Read ↗

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.Semantic proximity Read ↗

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Semantic proximity Read ↗

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.Semantic proximity Read ↗

TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.Semantic proximity Read ↗

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.Semantic proximity Read ↗

Predicting Anthracycline Benefit: <i>TOP2A</i> and CEP17—Not Only but AlsoSemantic proximity Read ↗

Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patientsSemantic proximity Read ↗

HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.